Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients

Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients

Objectives This study aims to describe the clinical outcomes of combination therapy with sarilumab and baricitinib for severe novel Coronavirus-19 (COVID-19) infection in cancer patients. With this study, we aim to evaluate the role of expanded immunotherapy for severely ill patients with COVID-19 r...

Full description

Bibliographic Details
Main Authors:	Ana Paula Velez, Guy Handley, Austin Morison, Ju Hee Katzman, Olga kinkhova, Rod Quiltz, John Greene, Yanina Pasikhova
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-09-01
Series:	Cancer Control
Online Access:	https://doi.org/10.1177/10732748231205864

Similar Items

Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
by: Yanina Pasikhova, et al.
Published: (2022-01-01)

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Sarilumab‐induced cutaneous adverse event
by: Sayaka Sato, et al.
Published: (2022-04-01)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Efficacy of baricitinib in severe coronavirus disease 2019
by: Ahmed M A E F Amer, et al.
Published: (2023-01-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
by: Paul Emery, et al.
Published: (2020-11-01)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2017)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
by: Giuseppe Russo, et al.
Published: (2024-04-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
by: Mar Masiá, et al.
Published: (2021-11-01)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
by: Sofia Faria, et al.
Published: (2023-09-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Baricitinib for alopecia areata
by: Hamza Imran, et al.
Published: (2023-04-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
by: Josef S Smolen, et al.
Published: (2023-08-01)

Thromboembolic safety of tofacitinib and baricitinib: An observational analysis of the WHO VigiBase
by: Enriqueta Vallejo-Yagüe, et al.
Published: (2020-10-01)

Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis
by: Zhaoling Wang, et al.
Published: (2022-09-01)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
by: Chan-yuan Wu, et al.
Published: (2023-09-01)

Baricitinib for the treatment of atopic dermatitis
by: Amelia Melo, et al.
Published: (2022-07-01)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Case of successful use of sarilumab in secondary renal amyloidosis in a patient with rheumatoid arthritis
by: L. A. Smirnova, et al.
Published: (2022-11-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
by: Su-Yeon Yu, et al.
Published: (2022-12-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
by: Maaike C. Swets, et al.
Published: (2023-04-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
by: Qian Gao, et al.
Published: (2022-12-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
by: Fournier M, et al.
Published: (2019-02-01)